ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Insys Therapeutics, Inc." (INSY) Report Updated: Sep 29, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Insys Therapeutics, Inc." (INSY)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: MDVN, MDXG, ITMN, CBMG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up downgrade
service keys

"Insys Therapeutics, Inc."© quotemedia

Company Profile

INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.

Recent News: "Insys Therapeutics, Inc."